Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
GHRS Stock Chart & Stats
$15.37
-$0.22(-2.41%)
At close: 4:00 PM EST
$15.37
-$0.22(-2.41%)
Day’s Range― - ―
52-Week Range$7.98 - $19.51
Previous CloseN/A
Volume14.35K
Average Volume (3M)525.32K
Market Cap
$940.68M
Enterprise Value$704.32M
Total Cash (Recent Filing)$288.51M
Total Debt (Recent Filing)$582.00K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Feb 26, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding62,029,396
10 Day Avg. Volume231,902
30 Day Avg. Volume525,319
Financial Highlights & Ratios
PEG Ratio-0.91
Price to Book (P/B)2.04
Price to Sales (P/S)0.00
P/FCF Ratio-8.60
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.12K
Enterprise Value/Ebitda-16.55
Forecast
1Y Price Target
$33.25Price Target Upside116.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst OutlookAnalyst increased the price target and reaffirmed a Buy rating based on a higher probability of success for GH001 after IND clearance, signaling stronger market confidence among research analysts.
Capital PositionStrong cash, cash equivalents, and marketable securities provide financial flexibility to fund a global pivotal program and reduce the need for near‑term dilutive financing.
Clinical DataPhase 2b and open‑label extension data showed rapid and durable remission and favorable tolerability for GH001, supporting the drug's potential to address unmet needs in treatment‑resistant depression.
Bears Say
Commercial And Competitive RiskIntense competition among short‑acting psychedelics, along with reimbursement and pricing pressures and potential future capital needs, could limit market share and pressure valuation even if clinical milestones are met.
Regulatory UncertaintyU.S. IND clearance does not guarantee approval in other jurisdictions, and the proprietary delivery device may face different review standards abroad, creating regulatory uncertainty for global commercialization.
Safety And Durability ConcernsOutstanding toxicology questions tied to animal respiratory histology and severe adverse events reported in the open‑label study raise clinical risks that could require additional safety studies or dosing adjustments.
GH Research News
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $7.98 and its highest was $19.51 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is $940.68M.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Feb 26, 2026 which is in 14 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Nov 06, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.237 by $0.007.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.27.
How many shares outstanding does GH Research have?
GH Research has 62,029,396 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.237. Following the earnings report the stock price went down -1.325%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in GHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.25 (116.33% Upside)
$33.25 (116.33% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.25%
12-Months-Change
Fundamentals
Return on Equity
-17.86%
Trailing 12-Months
Asset Growth
51.31%
Trailing 12-Months
Company Description
GH Research
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$33.25
▲(116.33% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
4.65% Mutual Funds
58.71% Other Institutional Investors
35.74% Public Companies and
Individual Investors